

1 **Detection of diphtheria toxin-producing *Corynebacterium ramonii* in wounds of an urban,**  
2 **inner-city population in Vancouver, Canada, 2019-2023**

3 Christopher F. Lowe<sup>1,2\*</sup>, Gordon Ritchie<sup>1,2\*</sup>, Chiara Crestani<sup>3</sup>, Miguel Imperial<sup>2,4</sup>, Nancy  
4 Matic<sup>1,2</sup>, Michael Payne<sup>1,2</sup>, Aleksandra Stefanovic<sup>1,2</sup>, Diana Whellams<sup>2,4</sup>, Sylvain Brisse<sup>3\*\*</sup>, Marc  
5 G. Romney<sup>1,2\*\*</sup>

6 <sup>1</sup>St. Paul's Hospital, Vancouver, Canada

7 <sup>2</sup>University of British Columbia, Vancouver, Canada

8 <sup>3</sup>Institut Pasteur, Paris, France

9 <sup>4</sup>LifeLabs, Vancouver, Canada

10 \*These first authors contributed equally to this work.

11 \*\*The senior authors contributed equally to this work.

12 Corresponding Author:

13 Christopher F. Lowe

14 1081 Burrard Street

15 Vancouver, BC

16 V6Z 1Y6

17 Canada

18 Tel: (604) 806-8422

19 Email: christopher.lowe@ubc.ca

20 **Article Summary**

21 Two distinct clusters of *C. ramonii* were identified in Vancouver, BC with clinical presentations  
22 similar to cutaneous *C. diphtheriae*.

23 **Running Title**

24 Diphtheria toxin-producing *C. ramonii* in wounds

25 **Abstract Word Count**

26 48

27 **Word Count**

28 1199

29 **Keywords**

30 diphtheria toxin, *Corynebacterium ulcerans*, cutaneous diphtheria, next-generation sequencing,  
31 MALDI-ToF

32

33 Abstract

34 We conducted a retrospective chart review and whole-genome sequencing of specimens with  
35 presumptive *Corynebacterium ulcerans* in Vancouver from July 2019 to July 2023. WGS  
36 confirmed 8/14 wound culture isolates as *C. ramonii*. Two distinct clusters of *C. ramonii* were  
37 identified with clinical presentations similar to cutaneous *C. diphtheriae*.

## 38 Introduction

39 *Corynebacterium ramonii*, a member of the *Corynebacterium diphtheriae* species  
40 complex, has recently been differentiated from *Corynebacterium ulcerans*(1). In addition to  
41 genomic differences, there may be epidemiological differences: *C. ulcerans* is associated with  
42 zoonotic transmission (predominantly infections in cats and dogs), while *C. ramonii* is suspected  
43 of potential human-to-human transmission, as its zoonotic character has not been established(1).  
44 *C. ulcerans* can present with respiratory or cutaneous infection similar to *C. diphtheriae*(2,3). To  
45 date, there have been 14 isolates characterized as *C. ramonii* in the literature(1), some of which  
46 have been reported to harbour the diphtheria toxin gene, potentially underscoring the clinical and  
47 public health implications of correctly identifying this organism.

48 In Canada, where the incidence of *C. ulcerans* is very low, there was a 35% increase in  
49 toxin testing referrals to the National Microbiology Laboratory (NML, Winnipeg, MB) between  
50 2006–2019; twenty-two cases of *C. ulcerans* infection were identified (45% diphtheria toxin  
51 positive)(4). While there have been multiple reports of non-toxigenic cutaneous diphtheria (*C.*  
52 *diphtheriae*) in the inner-city of Vancouver, there have only been sporadic reports of toxigenic *C.*  
53 *ulcerans*(5,6). In response to the detection of additional *C. ulcerans* cases in this community –  
54 most of which were subsequently identified as *C. ramonii* – we conducted a clinical,  
55 epidemiological, and genomic review of infections caused by this novel species.

## 56 Methods

57 A retrospective review of all specimens with presumptive “*C. ulcerans*” (based on  
58 MALDI-ToF) was performed by the St. Paul’s Hospital (SPH) microbiology laboratory and  
59 LifeLabs (Vancouver, BC) from January 2019 to July 2023. Chart extraction using electronic

60 medical records (EMR) was conducted for patients seen at SPH (no clinical information  
61 available for LifeLabs' cases) including: hospital course (inpatient/critical care admission);  
62 antibiotics; 30-day mortality; and risk factors for infection (housing status, substance use,  
63 livestock/domestic animal exposure). Bacterial cultures with *C. ulcerans* were characterized  
64 utilizing the MALDI Biotyper® Sirius System (Bruker). At SPH, antibiotic gradient strips  
65 (Etest, bioMérieux) were used to perform antibiotic susceptibility testing for penicillin,  
66 erythromycin, clindamycin and vancomycin(7). Toxin testing (PCR) and modified Elek test were  
67 performed at NML. For whole-genome sequencing (WGS), isolated bacterial colonies were  
68 extracted on the MagNA Pure 24 (Roche Diagnostics) and sequenced on the GridION (Oxford  
69 Nanopore Technologies) with R10.4.1 flowcells. Data acquisition and base-calling into fast5  
70 files was performed on MinKNOW (v.23.07.12) and Guppy (v.6.4.6). Raw FASTQ files were  
71 assembled with Flye v2.9. Genome assembly quality was checked with QUAST v5.2.0 and  
72 analysed with diphtOscan(8–10). A maximum-likelihood phylogeny with IQ-tree v2.3.4 and a  
73 GTR+G model was inferred from a core gene alignment obtained with panaroo v1.5.0 and  
74 visualised with Microreact [[https://microreact.org/project/rgLWfs1derHFm4K5ShbxgJ-c-ramonii-and-](https://microreact.org/project/rgLWfs1derHFm4K5ShbxgJ-c-ramonii-and-c-ulcerans-vancouver-canada)  
75 [c-ulcerans-vancouver-canada](https://microreact.org/project/rgLWfs1derHFm4K5ShbxgJ-c-ramonii-and-c-ulcerans-vancouver-canada)](11–13). Core genome multilocus sequence type (cgMLST) profiles  
76 were attributed by tagging the genomes for known alleles within BIGSdb-Pasteur  
77 [<https://bigsdb.pasteur.fr/diphtheria>] with the cgMLST\_ulcerans scheme. Minimum-spanning  
78 trees were obtained with GrapeTree directly from the BIGSdb-Pasteur plug-in(14,15).

79 Research ethics approval was obtained from the University of British  
80 Columbia/Providence Health Care Research Institute (H22-03695).

## 81 Results

82           There were 14 patients with cultures initially identified as *C. ulcerans* by MALDI-ToF.  
83   Further analysis of the spectra revealed 8/14 samples with a peak at 5405.40 m/z (range: 5404-  
84   5406 m/z) which has been associated with *C. ramonii*(1). WGS and genotyping confirmed these  
85   isolates as *C. ramonii*, including four sequence type (ST) 335 and four ST341 (Figure 1A), all  
86   originating from the inner-city of Vancouver (Figure 1B). Results of cgMLST typing suggest the  
87   existence of two *C. ramonii* clusters of recent transmission, with a maximum of one allelic  
88   mismatch for Cluster X and no allelic mismatches for Cluster Y (Figure 1A). The remaining six  
89   isolates were confirmed as *C. ulcerans* (ST325, ST339, ST669 [3 isolates] and ST895, a novel  
90   ST) (Figure 1C). In contrast to *C. ramonii*, they did not originate from a specific neighbourhood.

91           All specimens were polymicrobial and recovered from lower extremity wounds (Table 1).  
92   Antimicrobial susceptibility and toxigenicity data are reported in Table 1.

93           Chart review of patients with *C. ramonii* infection revealed 3/8 required admission to  
94   hospital (average length of stay, 6 days) with no critical care admissions and no 30-day  
95   mortality. Of the 6 patients with EMR documentation, all were treated with a course of  
96   antibiotics (piperacillin-tazobactam, amoxicillin-clavulanate, trimethoprim-sulfamethoxazole,  
97   cephalexin, cefazolin or ceftriaxone). All eight patients were associated with the downtown core  
98   of Vancouver (Figure 1B), including five persons experiencing homelessness (PEH);  
99   contrastingly, *C. ulcerans* cases were distributed throughout the city outside the downtown core  
100   (based on postal code). All *C. ramonii* patients reported a history of substance use disorder.  
101   Importantly, none had documented livestock or domestic animal exposure (i.e., pets).

102   Discussion

103 A review of *C. ramonii* and *C. ulcerans* recovered from wound cultures in Vancouver  
104 revealed distinct epidemiological differences between these closely related organisms. *C.*  
105 *ramonii* cases clustered exclusively in a single geographic region (inner-city downtown  
106 Vancouver), whereas *C. ulcerans* cases resided outside of the city's downtown core. Human-to-  
107 human transmission of *C. ramonii* has been hypothesized(1), and based on molecular,  
108 microbiological and epidemiological findings, this study suggests possible human-to-human  
109 transmission. WGS showed two distinct *C. ramonii* clusters (ST335 and ST341) within the same  
110 community. Vancouver's downtown core has high rates of poverty, PEH and substance use, and  
111 may be conducive to transmission via close contact, such as a previous cluster of cutaneous *C.*  
112 *diphtheriae* associated with a single strain(5). A similar pattern appears to be emerging for  
113 patients with *C. ramonii*, all of whom are from the same community. There were no reports of  
114 animal exposure, in contrast to the association of *C. ulcerans* with zoonotic transmission. *C.*  
115 *ramonii* was identified with other bacteria associated with human reservoirs, either exclusively  
116 or primarily: Group A *Streptococcus*, Group G *Streptococcus*, *A. haemolyticum*. All wound  
117 cultures were polymicrobial in nature (and one specimen harboured *P. multocida*). Based on our  
118 preliminary review, the clinical presentation of *C. ramonii* infections aligns more closely to the  
119 presentation of cutaneous diphtheria due to *C. diphtheriae*, rather than *C. ulcerans*(5).

120 Our study highlights the role for MALDI-ToF identification of *C. ramonii*. The initial  
121 description of *C. ramonii* reported a unique peak at 5405.40 m/z(1). In our study, initial *C.*  
122 *ramonii* identification required WGS, and retrospective review of the spectra confirmed the  
123 presence of the peak, though exhibiting a broader m/z range. With MALDI-ToF widely used in  
124 clinical laboratories, the prevalence of *C. ramonii* can be more accurately estimated when peak  
125 analysis of mass spectrograms is performed to avoid misidentification as *C. ulcerans*. This also

126 reinforces the need to continually update the MALDI-ToF spectral databases thus enabling  
127 accurate detection of emerging pathogens, such as *C. ramonii*.

128         Limitations of this study include the relatively small number of cases. Since wound  
129 cultures were polymicrobial, it is unclear to which degree *C. ramonii* contributed to the wound  
130 infection. No toxigenic systemic signs were observed in the three patients with diphtheria toxin-  
131 producing *C. ramonii*. In addition, we could not perform a formal case-control study, as the  
132 patients with *C. ulcerans* infection were primarily seen in outpatient clinics outside of our  
133 healthcare network, and complete medical records were not accessible.

134         Our findings correlate with the initial clinical description of *C. ramonii*, which appears to  
135 present similarly to cutaneous *C. diphtheriae* infections. As laboratories become increasingly  
136 proficient in differentiating *C. ulcerans* from *C. ramonii*, additional studies are required to better  
137 characterize this novel member of the *C. diphtheriae* species complex.

#### 138 Acknowledgements

139 We would like to thank Jennifer Bilawka and Leah Gowland for their technical support at the St.  
140 Paul's Hospital Microbiology Laboratory. We would like to thank the BCCDC Public Health  
141 Laboratory and National Microbiology Laboratory for coordinating and performing the toxin  
142 testing for this study.

#### 143 Author biography

144 Dr. Lowe is a Medical Microbiologist and Infection Prevention and Control Physician at St.  
145 Paul's Hospital in Vancouver, BC and a Clinical Professor at the University of British Columbia.

#### 146 Data availability



147 Sequence data for this project is available at <https://bigsd.bpasteur.fr/diphtheria/>, project number  
148 30. Phylogenetic analyses *C. ulcerans* and *C. ramonii*, together with all the relevant metadata, is  
149 available in Microreact at the project URL:

150 <https://microreact.org/project/rgLWfs1derHFm4K5ShbxgJ-c-ramonii-and-c-ulcerans-vancouver-canada>.

### 151 Conflict of Interest

152 No relevant conflict of interests to declare.

### 153 Funding and Open access license statement

154 This research was funded, in whole or in part, by Institut Pasteur. For the purpose of open access,  
155 the authors have applied a CC-BY public copyright license to any Author Manuscript version  
156 arising from this submission.

### 157 Authorship

158 Conceptualization, SB, MGR; Data curation, CFL, GR, CC, MF, MI, NM, MP, AS, DW; Formal  
159 analysis, CFL, GR, CC, MGR; Sequencing and analysis, GR, CC; Funding acquisition, N/A;  
160 Investigation, CFL, GR, CC, MF, MI, NM, MP, AS, DW; Methodology, CFL, GR, CC, MF, SB,  
161 MGR; Project administration, CFL, SB, MGR; Supervision, SB, MGR; Visualization, CFL, GR,  
162 CC; Writing – original draft, CFL; Writing – review & editing, CFL, GR, CC, MF, MI, NM, MP,  
163 AS, DW, SB, MGR.

164

165 References

- 166 1. Crestani C, Arcari G, Landier A, Passet V, Garnier D, Brémont S, et al. *Corynebacterium*  
167 *ramonii* sp. nov., a novel toxigenic member of the *Corynebacterium diphtheriae* species  
168 complex. Res Microbiol. 2023 Sep;174(7):104113.
- 169 2. Otshudiema JO, Acosta AM, Cassiday PK, Hadler SC, Hariri S, Tiwari TSP. Respiratory  
170 Illness Caused by *Corynebacterium diphtheriae* and *C. ulcerans* , and Use of Diphtheria  
171 Antitoxin in the United States, 1996–2018. Clin Infect Dis. 2021 Nov 2;73(9):e2799–806.
- 172 3. Moore LSP, Leslie A, Meltzer M, Sandison A, Efstratiou A, Sriskandan S.  
173 *Corynebacterium ulcerans* cutaneous diphtheria. Lancet Infect Dis. 2015 Sep;15(9):1100–  
174 7.
- 175 4. Bernard K, Pacheco A, Burdz T, Wiebe D. Increase in detection of *Corynebacterium*  
176 *diphtheriae* in Canada: 2006–2019. Canada Commun Dis Rep. 2019 Nov 7;45(11):296–  
177 301.
- 178 5. Chorlton SD, Ritchie G, Lawson T, Romney MG, Lowe CF. Whole-genome sequencing  
179 of *Corynebacterium diphtheriae* isolates recovered from an inner-city population  
180 demonstrates the predominance of a single molecular strain. J Clin Microbiol. 2020;58(2):  
181 e01651-19.
- 182 6. DeWinter LM, Bernard KA, Romney MG. Human Clinical Isolates of *Corynebacterium*  
183 *diphtheriae* and *Corynebacterium ulcerans* Collected in Canada from 1999 to 2003 but  
184 Not Fitting Reporting Criteria for Cases of Diphtheria. J Clin Microbiol. 2005  
185 Jul;43(7):3447–9.

- 186 7. CLSI. Methods fo Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently  
187 Isolated or Fastidious Bacteria. 3rd ed. CLSI guideline M45. Wayne, PA: Clinical and  
188 Laboratory Standards Institute; 2015.
- 189 8. Kolmogorov M, Yuan J, Lin Y, Pevzner PA. Assembly of long, error-prone reads using  
190 repeat graphs. *Nat Biotechnol.* 2019 May 1;37(5):540–6.
- 191 9. Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUASt: quality assessment tool for  
192 genome assemblies. *Bioinformatics.* 2013 Apr 15;29(8):1072–5.
- 193 10. Hennart M, Crestani C, Bridel S, Armatys N, Brémont S, Carmi-Leroy A, et al. A global  
194 *Corynebacterium diphtheriae* genomic framework sheds light on current diphtheria  
195 reemergence. *Peer Community J.* 2023 Aug 31;3:e76.
- 196 11. Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: A Fast and Effective  
197 Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. *Mol Biol Evol.*  
198 2015 Jan;32(1):268–74.
- 199 12. Tonkin-Hill G, MacAlasdair N, Ruis C, Weimann A, Horesh G, Lees JA, et al. Producing  
200 polished prokaryotic pangenomes with the Panaroo pipeline. *Genome Biol.* 2020 Dec  
201 22;21(1):180.
- 202 13. Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, Glasner C, et al. Microreact:  
203 visualizing and sharing data for genomic epidemiology and phylogeography. *Microb*  
204 *Genomics.* 2016 Nov 30;2(11).
- 205 14. Crestani C, Passet V, Rethoret-Pasty M, Criscuolo A, Zidane N, Bremont S, et al.  
206 Genomic Epidemiology and Microevolution of the Zoonotic Pathogen *Corynebacterium*

- 207            *ulcerans*. bioRxiv. 2024 Aug 22 [cited 2024 Sept 24];  
208            <https://doi.org/10.1101/2024.08.22.609154>
- 209    15.    Zhou Z, Alikhan N-F, Sergeant MJ, Luhmann N, Vaz C, Francisco AP, et al. GrapeTree:  
210            visualization of core genomic relationships among 100,000 bacterial pathogens. *Genome*  
211            *Res.* 2018 Sep;28(9):1395–404.

212

213

214 Table 1. Antimicrobial susceptibility testing, co-isolated bacteria from wound cultures and toxin  
 215 testing results from *Corynebacterium ulcerans* and *Corynebacterium ramonii* isolates.

	<i>Corynebacterium ulcerans</i> (n=6)	<i>Corynebacterium ramonii</i> (n=8)
<b>Antimicrobial Susceptibility</b>		
Penicillin	N/A	Intermediate (8)
Erythromycin	N/A	Susceptible (8)
Clindamycin	N/A	Susceptible (1); Intermediate (7)
Vancomycin	N/A	Susceptible (8)
<b>Frequency of bacteria co-isolated from wound cultures</b>	<i>Enterobacterales</i> (4) MSSA <sup>#</sup> (3) Coagulase-negative Staphylococci <sup>^</sup> (2) $\beta$ -hemolytic <i>Streptococcus</i> <sup>+</sup> (2) <i>Acinetobacter baumannii</i> (1)	$\beta$ -hemolytic <i>Streptococcus</i> * (6) <i>Arcanobacterium haemolyticum</i> (4) MSSA <sup>#</sup> (4) <i>Enterobacterales</i> (3) Yeast (1) <i>Pasteurella multocida</i> (1)
<b>Toxin Testing</b>		
Non-toxicogenic	4 (66.6%)	4 (50%)
Non-toxicogenic <i>tox</i> gene-bearing (NTTB)	0	1 (12.5%)

Toxigenic	2 (33.3%)	3 (37.5%)
-----------	-----------	-----------

216 \* *Streptococcus pyogenes* and *Streptococcus dysgalactiae* subsp. *equisimilis*

217 # Methicillin-susceptible *Staphylococcus aureus*

218 ^ *Staphylococcus pseudintermedius*, *Staphylococcus lugdunensis*

219 + *Streptococcus dysgalactiae* and Group G *Streptococcus*

220

221 Figure 1 *Corynebacterium ramonii* and *Corynebacterium ulcerans* isolates from Canada. A)  
222 Maximum-likelihood phylogeny and Minimum spanning tree of eight *C. ramonii* isolates from  
223 this study (British Columbia), together with two public isolates from Canada (Quebec); two  
224 clusters of infections can be observed, corresponding to ST335 and ST341 isolates. B) Spatial  
225 map of *C. ramonii* isolates from this study, all originating from downtown Vancouver. C)  
226 Maximum-likelihood phylogeny and Minimum spanning tree of six *C. ulcerans* isolates from  
227 this study (British Columbia). Trees were rooted at midpoint.

228

